NYSE:CBM - Cambrex Stock Price, Forecast & News

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

Cambrex Co. (NYSE:CBM) posted its earnings results on Thursday, October, 31st. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.24 by $0.01. The biotechnology company earned $148.56 million during the quarter. Cambrex had a return on equity of 5.38% and a net margin of 5.96%. View Cambrex's Earnings History.

Cambrex is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Cambrex.

5 equities research analysts have issued twelve-month target prices for Cambrex's stock. Their forecasts range from $43.00 to $60.00. On average, they anticipate Cambrex's stock price to reach $52.40 in the next twelve months. This suggests that the stock has a possible downside of 12.7%. View Analyst Price Targets for Cambrex.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cambrex.

Media stories about CBM stock have trended neutral recently, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cambrex earned a news impact score of 0.4 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Cambrex.

Cambrex saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 1,110,000 shares, a decline of 5.1% from the October 31st total of 1,170,000 shares. Based on an average daily trading volume, of 542,800 shares, the days-to-cover ratio is presently 2.0 days. Approximately 3.3% of the company's stock are short sold. View Cambrex's Current Options Chain.

Some companies that are related to Cambrex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), NVIDIA (NVDA), Intel (INTC), Under Armour (UAA), Broadcom (AVGO) and Juno Therapeutics (JUNO).

Cambrex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (3.05%), GW&K Investment Management LLC (1.35%), Gabelli Funds LLC (0.72%), GABELLI & Co INVESTMENT ADVISERS INC. (0.46%), Rhumbline Advisers (0.32%) and Millennium Management LLC (0.27%). Company insiders that own Cambrex stock include Dorothy A Donnelly-Brienza, Gregory B Brown, Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

CBM stock was sold by a variety of institutional investors in the last quarter, including Public Employees Retirement Association of Colorado, Summit Creek Advisors LLC, Stifel Financial Corp, Trillium Asset Management LLC, Confluence Investment Management LLC, Envestnet Asset Management Inc., First Trust Advisors LP and Voya Investment Management LLC. Company insiders that have sold Cambrex company stock in the last year include Dorothy A Donnelly-Brienza, Gregory B Brown, Gregory Sargen, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex.

CBM stock was acquired by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, GABELLI & Co INVESTMENT ADVISERS INC., Millennium Management LLC, Exane Asset Management, Dupont Capital Management Corp, Barclays PLC, Harvest Management LLC and GW&K Investment Management LLC. View Insider Buying and Selling for Cambrex.

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBM stock can currently be purchased for approximately $59.99.

Cambrex has a market capitalization of $2.02 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.View Additional Information About Cambrex.

The official website for Cambrex is http://www.cambrex.com/.

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]